281 related articles for article (PubMed ID: 20567910)
41. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
[TBL] [Abstract][Full Text] [Related]
42. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
43. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
44. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.
Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG
J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266
[TBL] [Abstract][Full Text] [Related]
45. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
[TBL] [Abstract][Full Text] [Related]
46. Fabry disease in children and the effects of enzyme replacement treatment.
Pintos-Morell G; Beck M
Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
[TBL] [Abstract][Full Text] [Related]
47. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
48. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
49. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
[TBL] [Abstract][Full Text] [Related]
51. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
52. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
53. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
54. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
55. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
56. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
57. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
[TBL] [Abstract][Full Text] [Related]
58. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22878505
[TBL] [Abstract][Full Text] [Related]
59. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
60. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
